TIAA CREF Investment Management LLC raised its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 36.2% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,924 shares of the company’s stock after buying an additional 6,091 shares during the period. TIAA CREF Investment Management LLC owned about 0.13% of Syndax Pharmaceuticals worth $315,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP boosted its position in shares of Syndax Pharmaceuticals by 8.3% in the first quarter. Wellington Management Group LLP now owns 2,539,820 shares of the company’s stock worth $34,847,000 after buying an additional 195,172 shares during the period. Granite Point Capital Management L.P. acquired a new position in shares of Syndax Pharmaceuticals during the first quarter worth $686,000. Trexquant Investment LP acquired a new position in shares of Syndax Pharmaceuticals during the first quarter worth $283,000. C WorldWide Group Holding A S acquired a new position in shares of Syndax Pharmaceuticals during the first quarter worth $163,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Syndax Pharmaceuticals by 43.5% in the first quarter. Bank of New York Mellon Corp now owns 29,227 shares of the company’s stock worth $401,000 after buying an additional 8,861 shares during the period. Hedge funds and other institutional investors own 70.68% of the company’s stock.

Shares of Syndax Pharmaceuticals, Inc. (SNDX) traded down 1.56% on Tuesday, hitting $11.99. 16,473 shares of the company were exchanged. The firm’s market cap is $266.41 million. Syndax Pharmaceuticals, Inc. has a 52-week low of $6.31 and a 52-week high of $16.40. The company has a 50-day moving average price of $12.39 and a 200 day moving average price of $11.94.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.09. The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.31 million. Syndax Pharmaceuticals had a negative return on equity of 58.23% and a negative net margin of 4,294.59%. Analysts predict that Syndax Pharmaceuticals, Inc. will post ($3.11) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “TIAA CREF Investment Management LLC Raises Position in Syndax Pharmaceuticals, Inc. (SNDX)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/29/tiaa-cref-investment-management-llc-raises-position-in-syndax-pharmaceuticals-inc-sndx.html.

A number of research analysts recently weighed in on SNDX shares. ValuEngine upgraded shares of Syndax Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, May 18th. Cowen and Company restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Tuesday, May 9th. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Tuesday, July 18th. Morgan Stanley restated an “overweight” rating and issued a $25.00 price objective (up previously from $24.00) on shares of Syndax Pharmaceuticals in a report on Monday, July 10th. Finally, Oppenheimer Holdings, Inc. set a $25.00 price objective on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 8th. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $23.78.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Stock Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.